ETHZilla Corporation Warrant (ATNFW) Stock Analysis
DELISTED 2025
What happened to ETHZilla Corporation Warrant (ATNFW) stock?
ETHZilla Corporation Warrant (ATNFW) no longer trades on public markets. It was delisted in August 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ETHZilla Corporation Warrant (ATNFW) trades at $0.43. ETHZilla Corporation Warrant (ATNFW) is associated with 180 Life Sciences Corp. , a clinical-stage biotechnology company. They focus on developing novel drugs for inflammatory diseases, fibrosis, and pain. Market cap: $2.60M, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for ATNFW: ATNFW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ATNFW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ATNFW: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →ETHZilla Corporation Warrant (ATNFW) Healthcare & Pipeline Overview
ETHZilla Corporation Warrant is linked to 180 Life Sciences Corp., a clinical-stage biotech firm targeting inflammatory diseases, fibrosis, and pain. Founded in 2016, the company leverages expertise from leading universities to develop novel therapeutics, operating within the competitive pharmaceutical sector.
What Is the Investment Thesis for ATNFW?
An investment in ETHZilla Corporation Warrant reflects the potential of 180 Life Sciences Corp.'s clinical-stage pipeline targeting inflammatory diseases, fibrosis, and pain. The company's approach of leveraging expertise from top universities provides a scientific foundation for its drug development programs. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The company's small market capitalization and limited employee count (4) indicate a high-risk, high-reward profile. Investors should closely monitor clinical trial progress and regulatory milestones to assess the potential for long-term value creation. The beta of 0.41 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
ATNFW Key Highlights
180 Life Sciences Corp. focuses on developing drugs for inflammatory diseases, fibrosis, and pain.
- The company was founded in 2016 by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard.
- Headquartered in Palo Alto, CA, 180 Life Sciences leverages expertise from Oxford University, the Hebrew University, and Stanford University.
- The company operates as a clinical-stage biotechnology company.
- The company's market cap is $0.00B, indicating a micro-cap status.
Who Are ATNFW's Competitors?
ATNFW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EIGRQ Eiger BioPharmaceuticals, Inc. | $8.50 | +6.25% | $12.6M | 54 |
| HIND Vyome Holdings Inc. | $2.28 | -1.72% | $16.0M | — |
| HEWA HealthWarehouse.com, Inc. | $0.11 | +0.00% | $6.29M | 55 |
| YI 111, Inc. | $3.44 | -1.99% | $30.1M | 44 |
| MYCOF Noveris Health Sciences Inc. | $0.73 | +0.00% | $42.7M | 48 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| HITI High Tide Inc. | $2.42 | -1.42% | $213M | 47 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.65 | +0.00% | $543M | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATNFW's Key Strengths?
Expertise in inflammatory diseases, fibrosis, and pain.
- Collaborations with leading universities.
- Proprietary drug candidates.
- Focus on unmet medical needs.
What Are ATNFW's Weaknesses?
Clinical-stage company with no approved products.
- Limited financial resources.
- Small employee count.
- Dependence on clinical trial outcomes.
What Could Drive ATNFW Stock Higher?
Clinical trial results for lead drug candidates.
- Regulatory submissions for potential drug approvals.
- Progress in research and development programs.
- Strategic partnerships and collaborations.
What Are the Key Risks for ATNFW?
Clinical trial failures.
- Regulatory delays or rejections.
- Competition from other pharmaceutical companies.
- Dependence on securing additional funding.
- Patent litigation or challenges to intellectual property.
What Are the Growth Opportunities for ATNFW?
- Expansion into New Therapeutic Areas: 180 Life Sciences can expand its focus to include additional inflammatory and fibrotic diseases beyond its current pipeline. The market for autoimmune and inflammatory disease treatments is projected to reach $150 billion by 2028, presenting a significant growth opportunity. Successful development and commercialization of new therapies in these areas could drive substantial revenue growth for the company.
- Strategic Partnerships and Collaborations: Partnering with larger pharmaceutical companies or research institutions can provide 180 Life Sciences with access to additional resources, expertise, and funding. Collaborative agreements can accelerate drug development timelines, expand market reach, and reduce financial risk. The company can pursue partnerships for specific drug candidates or platform technologies.
- Advancements in Drug Delivery Technologies: Utilizing innovative drug delivery systems, such as targeted nanoparticles or sustained-release formulations, can improve the efficacy and safety of 180 Life Sciences' drug candidates. These technologies can enhance drug bioavailability, reduce side effects, and improve patient compliance. Investing in drug delivery research and development can provide a competitive advantage.
- Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Europe, can increase the potential patient population for 180 Life Sciences' therapies. These regions have growing healthcare markets and increasing demand for innovative treatments. Establishing a presence in these markets through partnerships or direct operations can drive revenue growth and diversify the company's revenue streams.
- Orphan Drug Designations: Pursuing orphan drug designations for its therapies can provide 180 Life Sciences with market exclusivity, tax incentives, and expedited regulatory review. Orphan drug designations are granted to therapies targeting rare diseases or conditions affecting fewer than 200,000 people in the United States. This strategy can enhance the commercial attractiveness of the company's drug candidates.
What Are ATNFW's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Expertise in inflammatory diseases, fibrosis, and pain.
- Collaborations with leading universities.
- Established clinical trial infrastructure.
What Does ATNFW Do?
180 Life Sciences Corp., associated with ETHZilla Corporation Warrant (ATNFW), is a clinical-stage biotechnology company established on September 7, 2016, by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard. Headquartered in Palo Alto, CA, the company focuses on developing innovative drugs to address unmet medical needs in inflammatory diseases, fibrosis, and pain management. The company leverages the combined expertise of researchers from Oxford University, the Hebrew University, and Stanford University to advance its therapeutic programs. 180 Life Sciences is dedicated to translating cutting-edge research into effective treatments for conditions with limited therapeutic options. Their approach involves identifying and validating novel targets, developing proprietary drug candidates, and conducting rigorous clinical trials to demonstrate safety and efficacy. The company's pipeline includes programs targeting various inflammatory and fibrotic diseases, as well as chronic pain conditions. By focusing on areas with significant unmet needs, 180 Life Sciences aims to improve the lives of patients suffering from these debilitating conditions.
What Products and Services Does ATNFW Offer?
- Develops novel drugs for inflammatory diseases.
- Creates therapies for fibrosis.
- Researches treatments for chronic pain.
- Leverages expertise from Oxford University, the Hebrew University, and Stanford University.
- Conducts clinical trials to evaluate drug safety and efficacy.
- Identifies and validates novel drug targets.
How Does ATNFW Make Money?
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical research to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Out-licenses or commercializes approved drugs.
What Industry Does ATNFW Operate In?
180 Life Sciences Corp. operates within the competitive medical-pharmaceuticals industry. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical companies and other biotechnology firms. Market trends include a growing demand for novel therapies targeting chronic diseases, advancements in drug delivery technologies, and increasing regulatory scrutiny. The company's success depends on its ability to successfully navigate these challenges and bring its drug candidates to market.
Who Are ATNFW's Key Customers?
- Patients suffering from inflammatory diseases.
- Patients with fibrotic conditions.
- Individuals experiencing chronic pain.
- Healthcare providers prescribing treatments.
Company Profile
ETHZilla Corporation Warrant operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO Lloyd Blair Jordan. ATNFW has traded publicly since 2017.
ETHZilla Corporation Warrant Financial Trajectory
ETHZilla Corporation Warrant (ATNFW) reported $1.4M in revenue for Q2 2026, a decline of 52.3% compared to the prior quarter. The company recorded a net loss of $12.8M, with diluted EPS of $-0.75. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ATNFW averaged $-8.29 in diluted EPS.
How ETHZilla Corporation Warrant Is Valued
ETHZilla Corporation Warrant carries a market capitalization of $2.60M, placing it in the micro-cap category.
Financial Health
ETHZilla Corporation Warrant's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Forward Outlook
Wall Street analysts project ETHZilla Corporation Warrant revenue of about $30.4M for fiscal 2026, with EPS near $57.00.
ATNFW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in upcoming growth.
- Social sentiment has shifted positively, with discussions around innovative projects and potential partnerships gaining traction.
- Community members are highlighting the unique market position of ETHZilla, suggesting it could capitalize on emerging trends in the crypto space.
- Increased engagement on social platforms indicates a growing interest in the company's developments, which could translate to broader market support.
Bear Case
- Concerns about regulatory challenges in the cryptocurrency sector have led to skepticism among some investors, impacting overall sentiment.
- Recent negative news cycles regarding crypto volatility have cast a shadow over the company's reputation, making some traders cautious.
- Some community members are voicing doubts about the sustainability of ETHZilla's business model amid fierce competition.
- Insider selling in prior periods may raise questions about long-term commitment from executives, fueling bearish sentiment among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1M | -$13M | -$0.75 |
| Q1 2026 | $3M | -$76M | -$3.58 |
| Q4 2025 | $2M | -$230M | -$12.04 |
| Q3 2025 | $4M | -$209M | -$16.80 |
Based on FMP financials and quantitative analysis
ATNFW Latest News
No recent news available for ATNFW.
Leadership: Lloyd Blair Jordan
Unknown
Information on Lloyd Blair Jordan's background is not available in the provided data. Without additional context, it's challenging to provide a comprehensive biography. Further research would be needed to determine his career history, educational background, and previous roles before managing 180 Life Sciences Corp.
Track Record: Information on Lloyd Blair Jordan's track record is not available in the provided data. It is unknown what key achievements, strategic decisions, or company milestones have occurred under his leadership. Further research would be needed to assess his performance and contributions to the company.
Common Questions About ATNFW (Healthcare)
What happened to ETHZilla Corporation Warrant (ATNFW) stock?
ETHZilla Corporation Warrant (ATNFW) no longer trades on public markets. It was delisted in August 2025. The figures below are historical and are not a current quote.
Can I still buy ATNFW shares?
No. ATNFW stopped trading on public markets in August 2025, so the shares are not available through a broker. Anything you see quoted for ATNFW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ATNFW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to ETHZilla Corporation Warrant. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does ETHZilla Corporation Warrant do?
ETHZilla Corporation Warrant is associated with 180 Life Sciences Corp., a clinical-stage biotechnology company focused on developing novel drugs for inflammatory diseases, fibrosis, and pain. The company leverages expertise from leading universities to identify and validate drug targets, conduct clinical trials, and seek regulatory approvals.
What are the main risks for ATNFW?
The primary risks for ETHZilla Corporation Warrant, linked to 180 Life Sciences Corp., include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. Clinical trial failures can significantly impact the company's pipeline and valuation. Regulatory delays or rejections can delay or prevent drug approvals. Competition from larger companies with greater resources can limit market share.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- AI analysis pending.
- Information based on available sources as of 2026-03-18.